DS
ALLO icon

Daniel Sundheim’s Allogene Therapeutics ALLO Stock Holding History

Daniel Sundheim’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500,000
Closed -$21.4M – 50
2020
Q2 		$21.4M Buy
+500,000
New +$18.1M 0.16% 44

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Daniel Sundheim's ALLO Position: Q3 2020 in Review

Daniel Sundheim sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 500,000 shares — an estimated $21.4M sold.

Daniel Sundheim first reported a position in ALLO in Q2 2020 and held it in 1 quarter. The position peaked at $21.4M in Q2 2020. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

  • Daniel Sundheim reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Daniel Sundheim sold 500,000 Allogene Therapeutics shares in Q3 2020, an estimated $21.4M.
  • Daniel Sundheim first reported a position in Allogene Therapeutics in Q2 2020 and held it in 1 quarter.
  • Daniel Sundheim's Allogene Therapeutics position peaked at $21.4M in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on D1 Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.